Healthcare ❯Pharmaceuticals ❯Drug Approval

Clinical Trials

Efficacy ALS Treatment

FDA Approves First Standalone Nasal Spray for Treatment-Resistant Depression

Johnson & Johnson's Spravato becomes the first monotherapy for adults with major depressive disorder unresponsive to oral antidepressants.

ALS Drug Relyvrio Fails Key Clinical Trial, May Be Pulled from Market